# US 2015/0104473 A1 · Adjuvant compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104473 A1
- Document ID: US20150104473A1
- Status: Published application
- Kind: A1
- Application number: 14/349,652
- Filed: 2012-10-04
- Published: 2015-04-16
- Earliest claimed: 2011-10-05
- Assignees: ISA Pharmaceuticals B.V.
- Applicants: ISA Pharmaceuticals B.V.
- Inventors: Ferdinand Antonius Ossendorp; Cornelis Johannes Maria Melief; Selina Khan; Dmitri Viktorovistj Filippov; Gijsbert Arie Van Der Marel
- Web page: https://patentgrep.com/patent/US20150104473A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/50: the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6801: {Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent}
- A61P 37/04: Immunostimulants
- C07K 7/04: Linear peptides containing only normal peptide links
- C07K 7/06: having 5 to 11 amino acids
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55516: {Proteins; Peptides}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention is directed to a compound according to the formula [1] wherein R1 and R2 are branched or straight groups having up to 17 atoms selected from carbon, nitrogen, oxygen and sulphur, n is 0 to and including 18, Y is sulphur or selene, X is S or 0 and R is —OH or an organic group comprising one or more peptides, one or more nucleic acids, one or more antibodies or combinations thereof. The invention is also directed to process for preparing said compound and the use of said compound as an adjuvant. The invention is also directed to a composition comprising said compound and the use of said composition, for example as a vaccine composition.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A compound represented by the following formula [1]:
wherein R1 and R2 are each independently a branched or straight group having up to 17 atoms selected from carbon, nitrogen, oxygen and sulphur, n is 0 to and including 18, Y is sulphur or selene, X is S or O and R is —OH or an organic group comprising one or more peptides, one or more nucleic acids, one or more antibodies or combinations thereof.

### Claim 21 (depends on 20)

The compound according to claim 20, wherein X is O.

### Claim 22 (depends on 20)

The compound according to claim 20, wherein Y is sulphur.

### Claim 23 (depends on 20)

The compound according to claim 20, wherein R1 and R2 are each independently a straight alkyl group having 10 to 17 carbon atoms.

### Claim 24 (depends on 23)

The compound according to claim 23, wherein R1 and R2 are straight alkyl groups having 15 carbon atoms.

### Claim 25 (depends on 20)

The compound according to claim 20, wherein n is 11, 12 or 13.

### Claim 26 (depends on 20)

The compound according to claim 20, wherein R is an organic group comprising one or more peptides, and wherein R is optionally coupled to an antigen.

### Claim 27 (depends on 26)

The compound according to claim 26, wherein R is SKm (SEQ ID NO: 17) and wherein m is 1, 2, 3, 4 or 5.

### Claim 28 (depends on 26)

The compound according to claim 26, wherein group R is represented by
in which R4 is a Km (SEQ ID NO: 19) peptide part, wherein m is 0, 1, 2, 3, 4 or 5, and wherein R4 is optionally coupled to an antigen and in which R5 is hydrogen or a group comprising one to six atoms chosen from carbon, nitrogen and oxygen.

### Claim 29 (depends on 28)

The compound according to claim 28, wherein R5 is a —CH—OH group, a —CH2—CH3 group, a —(CH2)3—CH3 group, a —CH2C≡CH group, a —CH2CH═CH2 group or a —(CH2)2NH2 group.

### Claim 30 (depends on 28)

The compound according to claim 28, wherein R5 is not hydrogen and the asymmetric carbon to which R5 is attached has the L configuration.

### Claim 31 (depends on 28)

The compound according to claim 28, wherein the Km (SEQ ID NO: 19) peptide part is coupled to an antigen, a nucleic acid and/or an antibody.

### Claim 32 (depends on 20)

A solid phase peptide synthesis process to prepare a compound according to claim 20, comprising
(a) providing R—H, which is optionally immobilized and/or side-chain protected;
(b) coupling of substituted cysteine building block Fmoc-(Y-(2-(OC(O)R2)-3-(OC(O)R1))propyl)-Cys-OH to R—H; and
(c) cleaving the Fmoc-group from the N-terminus of the resulting peptide; and
(d) treating the Fmoc-liberated peptide with H—(CH2)n—N═C═X,
wherein R, R1, R2, X, Y and n are defined as in claim 20.

### Claim 33 (depends on 32)

The process according to claim 32, wherein R is an organic group comprising one or more peptides and R—H is immobilized and/or side-chain protected.

### Claim 34 (depends on 33)

The process according to claim 33, further comprising:
(e) conjugating an antibody or a nucleic acid to the H—(CH2)n—N═C═X-treated peptide.

### Claim 35 (depends on 20)

A composition comprising the compound according claim 20 and an antigen.

### Claim 36 (depends on 35)

The composition according to claim 35, wherein the antigen is conjugated to the compound.

### Claim 37 (depends on 35)

The composition according to claim 35, which is a vaccine against the antigen.

### Claim 38 (depends on 20)

A method for the induction, maintenance and/or enhancement of an immune response in a subject against an antigen and/or for the prevention, delay and/or treatment of a disease or condition associated with an antigen in a subject, comprising administering to the subject a composition comprising a compound according to claim 20 and an antigen.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the antigen is conjugated to the compound.
